The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And
https://optibiotix.com/conscious-eating-and-its-impact-on-lowering-blood-pressure/
mol
31 July 2023
https://optibiotix.com/the-triple-threat-probiotics-and-their-evolution-on-heart-cognitive-and-gut-health/
mol
Agree.
Today's RNS suggests that while Europe and America will be the main focus, there's no harm in setting in train some action elsewhere if it doesn't distract.
Probiotix Health Denmark ApS
As formed after year end no mention as a 100% subsidiary within our 31 dec accounts
https://ownr-dk.translate.goog/users/public-profile/4009554044?_x_tr_sl=da&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
however continues to be a bit disingenuous perhaps not to either acknowledge existence thereof or take measures to remove same from danish register
mol
Available
https://probiotixhealth-ir.com/docs/probiotixhealthlibraries/archive/circulars/proxy-results-agm-2023.pdf
mol
Agree. Can't be bothered to go thru a broker. I would be adding small, regular amounts but I imagine broker costs would be prohibitive. Tho' TBF I haven't tried.
I've also got the ones we got because of the OPTI stock divi. I would have definitely bought more shares at these prices if it had been on AIM. Unfortunately all my shares are held with stockbrokers that don't deal with Aquiss, so if I wanted to buy or sell, I would need to transfer the PBX shares to a stockbroker that does deal with Aquiss, I decided to wait and hope PBX get's moved to the AIM exchange.
That is the plan, to list on AIM. Unless it gets bought out before :-p
I only own what I own because of my Optis stock. If this was onAIM, Iwoild have bought a good bit more at the depressed price it has been.
I suspect that goes for a lot of other people too.
The day this is listed on a proper exchange, the market cap will see a terrific rise IMO
Hi martinu
I'm not sure why it was recently uploaded as I suspect it was made before PBX spun out as the new formulations not in slide presented and no mention of pbx.
As to eventual ownership possibly opti as they own LPgos but lpldl , as you note, resides with probiotix health (presumably.....?)
mol
Thanks for sharing. I guess this is a little way from production / commercialisation? Some general thoughts. Would this product be owned by Opti /PBX or jointly? Is it direct competition for LPldl/ Cholbiome?
YES baby about time, been a long time coming me thinking and where it is the SP is crazy tbf, rerate after AGM maybe and the folks buying this price must be so happy if Steve delivers 100 mc in 2-3 years time :o)
This is a gift. But, as has been said, a pain in the neck to buy. Good to see it finally moving back up.
Seems like a good appointment today. I imagine Steen knows him well, so makes sense.
Zac Mir has spoken :)
https://www.share-talk.com/traders-cafe-with-zak-mir-bulletin-board-heroes-monday-24th-july-2023/
Would be nice to see this SP pick up, in line with Opti.
Https://www.synctherapy.ca/seed-probiotics-reviews/
15 July
whilst not perhaps the most widespread site in Canada (ok tongue in cheek)- a useful summary nonetheless of our major customer to date - hopefully Steen will deliver many more seeds during 2023 and beyond - 6 month results to June 2023 will give an indication if he will be, possibly the only SOH appointed CEO or otherwise, to actually not only be able to work with same but actually deliver substantial revenue growth but also more importantly growing profits
mol
https://www-bio***a-co-il.translate.goog/umanaflora-lpdl-category5?_x_tr_sl=iw&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
one more try
mol
another new product
humanflora lpldl is a nutritional supplement - an innovative probiotic that contains a safe probiotic strain
without side effects that has been scientifically studied in several experiments for its beneficial effect on reducing cholesterol values. all of these make the humanaflora lpldl probiotic supplement a groundbreaking
and innovative alternative available.
the concentration of live bacteria in the capsule corresponds to the concentration of the probiotics that showed
beneficial results in their clinical trial with the lpldl strain
albeit the box looks like name is umanflora - perhaps translation wrong - anyway another product
https://rambam--medicine-org-il.translate.goog/shop/product/humanflora-lpldl/?_x_tr_sl=iw&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
and also here
https://www-bio***a-co-il.translate.goog/umanaflora-lpdl-category5?_x_tr_sl=iw&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc
mol
Why would you believe anything SOH says? He has been FOS for years!
Patience the sp is depressed due to sellers cashing in on free shares. SoH has said highly likely PBX will be sold via trade sales in 2-3 years >£50m so accumulate now at depressed levels and sit tight. Huge rerate in this share coming as sellers dry up and buyers take control.
3p to sell.
What an absolute joke. Either this is completely undervalued or it's priced to go out of business.
No point selling (if even possible); one of TW's worst tips.
Some extracts from the "Outlook"
ProBiotix has traded strongly since the beginning of the new financial year and has a strong order book from existing and new customers. Our CEO Steen Dannemann Andersen is already leveraging his industry-leading contacts to introduce
ProBiotix to new customers, some of which – including SymbioPharm one of the top three probiotic brands in Germany – have already placed a significant order.
We are also enjoying continued strong growth in e-commerce sales direct to consumers albeit ongoing issues with our supply chain has impacted on the availability of our best-selling product CholBiomeX3. The Company identified a new
manufacturer in 2022 and first orders were supplied in H1 2023.
CEOs strategy
...
In the first phase of implementation of this strategy, we will concentrate on expanding our sales structure in Europe and the Middle East, and building a platform for growth in North America, before moving in the medium term to explore the potential of additional markets in the Asia Pacific region, South America and South Africa. We will also seek to prove the potential for direct-to-consumer sales, focusing initially on the UK.
This strategy presents a clear five-year pathway for ProBiotix Health to build annual sales of £10 million while shifting the balance of the business from deriving 85% of turnover from bulk sales of LPLDL® in 2022 to making 85% of sales from finished products. To support this new strategic focus and ensure the delivery of the expected results we will need to make changes to the internal structure of the business and recruit additional personnel, including a
sales director for Europe and the Middle East and new sales manager for North America, together with an operations manager and a development scientist to add impetus to our product development.
Recruitment and additional staffing costs mean that whilst we expect sales to grow in 2023 the additional investment will impact on profitability in 2023, but will form a much stronger platform to deliver growth and shareholder value in the medium and longer term.